Abstracts tagged "ANCA"

Abstract Number: 126 • 2016 ACR/ARHP Annual Meeting
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in African-American Patients: Disease Associations and Clinical Outcomes in an Urban Cohort
Philip McCarthy¹, Jenna Hudy², Marie Melville², Danielle Robson¹, John McKinnon², Sandeep Soman² and Kathleen Maksimowicz-McKinnon³, ¹Michigan State University College of Osteopathic Medicine, East Lansing, MI, ²Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African-American populations. The significance of and associations with ANCA in African-Americans,…
Abstract Number: 1940 • 2016 ACR/ARHP Annual Meeting
High Prevalence of Inflammatory Heart Disease in Eosinophillic Granulomatosis with Polyangiitis (Churg Strauss) Patients
Eloi Garcia Vives¹, Len Harty² and David Jayne³, ¹Vall d'Hebrón Hospital, Barcelona, Spain, ²Vasculitis & Lupus, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom
Background/Purpose: To establish EGPA/Churg Strauss inflammatory heart disease prevalence and develop an algorithm for heart disease screening in EGPA patients. Methods: An audit of all…
Abstract Number: 3045 • 2016 ACR/ARHP Annual Meeting
Immunometabolism in ANCA-Associated Glomerulonephritis
Peter C. Grayson¹, Sean Eddy², Viji Nair², Hemang Parikh³, Maja Lindenmeyer⁴, Laura Mariani², Huateng Huang², Wenjun Ju³, Casey Greene⁵, Clemens Cohen⁴, Jeffrey Krischer³, Matthias Kretzler², Peter A. Merkel⁶ and Felix H. Eichinger², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Division of Nephrology, University of Michigan, Ann Arbor, MI, ³University of South Florida, Tampa, FL, ⁴University of Munich, Munich, Germany, ⁵Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Mounting an inflammatory response requires immune cells to undergo major changes in metabolism. Mediators such as cytokines can specifically alter the metabolism of different…
Abstract Number: 127 • 2016 ACR/ARHP Annual Meeting
Disease Characteristics and Outcomes in African-American Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: a High Risk Group for Poor Outcomes
Philip McCarthy¹, Danielle Robson¹, Jenna Hudy², Marie Melville², John McKinnon², Sandeep Soman² and Kathleen Maksimowicz-McKinnon³, ¹Michigan State University College of Osteopathic Medicine, East Lansing, MI, ²Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Antineutrophil antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African American populations. Little is known about the characteristics and outcomes of…
Abstract Number: 1941 • 2016 ACR/ARHP Annual Meeting
Retrospective Survey of Concomitant Autoimmune Diseases and Autoantibodies in a Cohort of Patients with ANCA-Associated Vasculitis (AAV)
Marta Casal Moura^1,2, Sergio Prieto-González², Georgina Espígol-Frigolé², Giuseppe Murgia^2,3, Marco Alba², Jose Hernández-Rodríguez² and Maria C. Cid², ¹Department of Internal Medicine, São João Hospital Center, Porto, Portugal, ²Hospital Clínic. University of Barcelona. IDIBAPS, Vasculitis Research Unit. Department of Autoimmune Diseases, Spain, Barcelona, Spain, ³University Clinic for Visceral Surgery and Medicine Bauchzentrum Bern, Bern, Switzerland
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) - granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) have heterogenous clinic…
Abstract Number: 3046 • 2016 ACR/ARHP Annual Meeting
Inflammatory Pathways As Shared Molecular Targets Across ANCA-Associated Vasculitis and Nephrotic Syndrome
Sean Eddy¹, Viji Nair¹, Hemang Parikh², Maja Lindenmeyer³, Laura Mariani¹, Felix H. Eichinger¹, Huateng Huang¹, Wenjun Ju², Casey Greene⁴, Peter C. Grayson⁵, Clemens Cohen³, Jeffrey Krischer², Peter A. Merkel⁶ and Matthias Kretzler¹, ¹Division of Nephrology, University of Michigan, Ann Arbor, MI, ²University of South Florida, Tampa, FL, ³University of Munich, Munich, Germany, ⁴Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Clinical trials in rare diseases typically test therapeutic efficacy in one disease defined by a particular clinical phenotype. Improved understanding of the molecular mechanisms…
Abstract Number: 978 • 2016 ACR/ARHP Annual Meeting
A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis
Peter A. Merkel¹, John Niles², Richard Jimenez³, Robert F. Spiera⁴, Brad H. Rovin⁵, Andrew Bomback⁶, Christian Pagnoux⁷, Antonia Potarca⁸, Thomas J. Schall⁹ and Pirow Bekker⁹, ¹Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ²Massachusetts General Hospital, Boston, MA, ³Rheumatology, The Seattle Arthritis Clinic, University of Washington Medicine, Northwest Hospital and Medical Center, Seattle, WA, ⁴Hospital for Special Surgery, Cornell, New York, NY, ⁵Ohio State University Medical Center, Columbus, OH, ⁶Columbia University Medical Center, New York, NY, ⁷Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ⁸ChemoCentryx, Inc., Mountain View, CA, ⁹ChemoCentryx, Mountain View, CA
Background/Purpose: Complement 5a (C5a) is involved in the pathogenesis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). CCX168 is an orally administered, small molecule selective inhibitor of…
Abstract Number: 1942 • 2016 ACR/ARHP Annual Meeting
Presentation and Clinical Features of ANCA-Associated Vasculitis in US African Americans: Experience from a Single Center
Sebastian Sattui¹, Andrew Westfall² and Angelo L. Gaffo³, ¹Tinsley Harrison Internal Medicine Residency Program, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, Birmingham VA Medical Center, Birmingham, AL
Title: Presentation and Clinical Features of ANCA-associated Vasculitis in US African Americans: Experience From a Single Center Background/Purpose: Little is known about the presentation,…
Abstract Number: 3179 • 2016 ACR/ARHP Annual Meeting
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Joanna C. Robson^1,2,3, Jill Dawson⁴, Judy A. Shea⁵, Helen Doll⁶, Susan Ashdown⁷, Renee Borchin⁸, Ebony Easley⁹, John T. Farrar¹⁰, Don Gebhart¹¹, Katherine Kellom¹², Georgia Lanier¹³, Raashid Luqmani¹⁴, Carol A McAlear¹⁵, John Mills¹⁶, Nataliya Milman^17,18,19, Jacqueline Peck⁷, Gunnar Tomasson²⁰, Peter F. Cronholm⁹ and Peter A. Merkel²¹, ¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ²Department of Rheumatology, University Hospitals Bristol NHS Trust, Bristol, United Kingdom, ³School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁵Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Department of Population Health, University of East Anglia, Norwich, United Kingdom, ⁷Oxford, Oxford, United Kingdom, ⁸University of South Florida, Tampa, FL, ⁹Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Columbus, Columbus, OH, ¹²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ¹³NONE, Framingham, MA, ¹⁴NDORMS , Rheumathology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁵Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Vasculitis UK, Sheffield, United Kingdom, ¹⁷Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ¹⁸The Ottawa Hospital, Ottawa, ON, Canada, ¹⁹Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²⁰Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ²¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and…
Abstract Number: 980 • 2016 ACR/ARHP Annual Meeting
Short-Course Glucocorticoids in ANCA-Associated Vasculitis: A Proof of Concept Study
Eli Miloslavsky¹, John Niles², Karen Laliberte², Katherine Cosgrove² and John H. Stone³, ¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Despite therapeutic advances in ANCA-associated vasculitis (AAV), patients continue to be exposed to considerable treatment morbidity from long-term glucocorticoid (GC) use. The optimal duration…
Abstract Number: 1943 • 2016 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse
Maxime Samson¹, Hervé Devilliers², Xavier Puéchal³, Christian Pagnoux⁴, Pascal Cohen³, Luc Mouthon³, Benjamin Terrier⁵ and Loïc Guillevin³, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: To identify associations between patients’ clinical and biological characteristics at diagnosis of antineutrophil cytoplasmic antibody-associated vasculitides (AAVs), and their relapse during follow-up. Methods: Long-term…
Abstract Number: 3180 • 2016 ACR/ARHP Annual Meeting
Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis
Sarah M Moran¹, Michelle Ryan¹, Paul A. Monach², David Cuthbertson³, Simon Carette⁴, Jean Dunne⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁹, Carol A. McAlear¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁴, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹⁴, Steven R. Ytterberg¹⁵, Lina Zgaga¹⁶, Peter A. Merkel¹⁷, Mark A. Little¹⁸ and the Vasculitis Clinical Research Consortium, ¹Clinical Medicine, Trinity Health Kidney Centre, Dublin, Ireland, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Immunology Department, St James's Hospital, Dublin, Ireland, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴Rheumatology, The University of Pennsylvania, Philadelphia, PA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Public Health and Primary Care, Trinity College Dublin, Dublin, Ireland, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Clinical Medicine, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples from patients with…
Abstract Number: 999 • 2016 ACR/ARHP Annual Meeting
Utility of Neutrophil CD64 Expression & sTREM-1 in Distinguishing Bacterial Infection from Disease Flare in SLE and ANCA Associated Vasculitis
Sajal Ajmani, Harshit Singh, Saurabh Chaturvedi, Mohit kumar Rai and Vikas Agrawal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Fever is a common presenting manifestation of systemic lupus erythematosus (SLE) and ANCA associated vasculitis (AAV). Treating physician is challenged to differentiate between disease…
Abstract Number: 1944 • 2016 ACR/ARHP Annual Meeting
Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis
Zachary Wallace¹, Eli Miloslavsky², Sebastian H. Unizony³, Na Lu⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol A. Langford⁷, Peter A. Merkel⁸, Paul A. Monach⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene William St.Clair¹², Paul Bruntetta¹³, Matthew Cascino¹⁴, Hyon K. Choi¹⁵ and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, Cornell, New York, NY, ¹²Rheumatology and Immunology, Duke University, Durham, NC, ¹³Genentech, Inc., South San Francisco, CA, ¹⁴University of California-San Francisco, San Francisco, CA, ¹⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) treatment includes high dose glucocorticoids (GCs), which are associated with increased body-mass index (BMI), a complication abhorred by patients and associated…
Abstract Number: 1215 • 2016 ACR/ARHP Annual Meeting
Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes
Aya Kawasaki¹, Daisuke Tsukui², Yuya Kondo³, Yoshitaka Kimura², Kurumi Asako², Hiroshi Furukawa¹, Hajime Kono², Takayuki Sumida⁴ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interferon (IFN) signature has been established in the peripheral blood of the patients with systemic lupus erythematosus (SLE) by transcriptome analyses, indicating a role…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].